• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在接受抗毒蕈碱药物治疗的膀胱过度活动症患者中,膀胱过度活动症症状评分的改善与健康相关生活质量问卷之间的相关性。

Correlation between improvements in Overactive Bladder Symptom Score and health-related quality of life questionnaires in overactive bladder patients treated with an antimuscarinic drug.

机构信息

Department of Nephro-urology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.

出版信息

Neurourol Urodyn. 2011 Sep;30(7):1309-14. doi: 10.1002/nau.21065. Epub 2011 May 10.

DOI:10.1002/nau.21065
PMID:21560155
Abstract

AIMS

To evaluate the relationship between treatment-related changes in Overactive Bladder Symptom Scores (OABSS) and health-related quality of life (HRQOL) questionnaires.

METHODS

Ninety-five patients with OAB symptoms were enrolled. All patients completed the OABSS, International Prostate Symptom Score (IPSS)-Quality Of Life (QOL) index and King's Health Questionnaire (KHQ) at enrollment and then again 4, 8, and 12 weeks after treatment with propiverine hydrochloride 10 mg twice daily. We evaluated the relationship between treatment-related changes in the OABSS, IPSS-QOL, and KHQ.

RESULTS

Statistically significant improvements were observed in all 4 OABSS subscales and total OABSS from baseline to 4 weeks with further improvements occurring at 12 weeks (all P < 0.01). The OABSS after antimuscarinic treatment correlated positively with both the IPSS-QOL index and KHQ domain scores. There was a moderate but statistically significant correlation between the change in total OABSS and 2 OABSS subscales (urinary urgency and urge incontinence) and improvement in the IPSS-QOL index (P < 0.01). Treatment-related changes in total OABSS were significantly correlated with changes in six KHQ domains. Moderate but statistically significant correlations were observed between the change in total OABSS and impact on life, physical limitations, emotions, and severity measures (r > 0.30, P < 0.05). Small but statistically significant correlations were observed between the change in total OABSS and role limitations or social limitations (P < 0.05).

CONCLUSIONS

Improvement in the OABSS correlated with improvements in HRQOL after treatment. The OABSS is a useful tool to evaluate OAB symptom severity after medical treatment.

摘要

目的

评估与过度膀胱症状评分(OABSS)和健康相关生活质量(HRQOL)问卷相关的治疗变化之间的关系。

方法

共纳入 95 例 OAB 症状患者。所有患者在入组时均完成 OABSS、国际前列腺症状评分(IPSS)-生活质量(QOL)指数和 King's 健康问卷(KHQ),然后在接受盐酸丙哌维林 10mg 每日 2 次治疗后 4、8 和 12 周再次进行评估。我们评估了 OABSS、IPSS-QOL 和 KHQ 治疗相关变化之间的关系。

结果

所有 4 个 OABSS 子量表和 OABSS 总分均从基线到 4 周时观察到统计学显著改善,12 周时进一步改善(均 P<0.01)。抗毒蕈碱治疗后的 OABSS 与 IPSS-QOL 指数和 KHQ 域评分均呈正相关。总 OABSS 的变化与 2 个 OABSS 子量表(尿急和急迫性尿失禁)和 IPSS-QOL 指数的改善呈中度但具有统计学显著相关性(P<0.01)。总 OABSS 的治疗相关变化与六个 KHQ 域的变化显著相关。总 OABSS 的变化与生活影响、身体限制、情绪和严重程度测量之间观察到中度但具有统计学显著相关性(r>0.30,P<0.05)。总 OABSS 的变化与角色限制或社会限制之间观察到小但具有统计学显著相关性(P<0.05)。

结论

治疗后 OABSS 的改善与 HRQOL 的改善相关。OABSS 是评估医疗治疗后 OAB 症状严重程度的有用工具。

相似文献

1
Correlation between improvements in Overactive Bladder Symptom Score and health-related quality of life questionnaires in overactive bladder patients treated with an antimuscarinic drug.在接受抗毒蕈碱药物治疗的膀胱过度活动症患者中,膀胱过度活动症症状评分的改善与健康相关生活质量问卷之间的相关性。
Neurourol Urodyn. 2011 Sep;30(7):1309-14. doi: 10.1002/nau.21065. Epub 2011 May 10.
2
OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.肉毒杆菌毒素 A 100U 显著改善伴有尿急和尿失禁的膀胱过度活动症患者的所有特发性膀胱过度活动症症状和生活质量:一项随机、双盲、安慰剂对照试验。
Eur Urol. 2013 Aug;64(2):249-56. doi: 10.1016/j.eururo.2013.04.001. Epub 2013 Apr 10.
3
Clinical relevance of health-related quality of life outcomes with darifenacin.达非那新治疗对健康相关生活质量结果的临床相关性。
BJU Int. 2008 Jul;102(2):208-13. doi: 10.1111/j.1464-410X.2008.07523.x. Epub 2008 Jul 1.
4
Responsiveness and minimal clinically important change in overactive bladder symptom score.膀胱过度活动症症状评分的反应性和最小临床重要变化。
Urology. 2011 Oct;78(4):768-73. doi: 10.1016/j.urology.2011.06.020.
5
Symptom severity and patient perceptions in overactive bladder: how are they related?膀胱过度活动症的症状严重程度和患者感知:它们之间有何关联?
BJU Int. 2009 Oct;104(7):968-72. doi: 10.1111/j.1464-410X.2009.08498.x. Epub 2009 Mar 10.
6
Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study.奥昔布宁透皮系统改善膀胱过度活动症成年患者的生活质量:一项基于社区的多中心随机研究。
BJU Int. 2007 Apr;99(4):836-44. doi: 10.1111/j.1464-410X.2006.06658.x. Epub 2006 Dec 20.
7
Comparison of fesoterodine and tolterodine in patients with overactive bladder.非索罗定与托特罗定治疗膀胱过度活动症患者的比较。
BJU Int. 2008 Nov;102(9):1128-32. doi: 10.1111/j.1464-410X.2008.07907.x. Epub 2008 Jul 21.
8
The translation and validation of Chinese overactive bladder symptom score for assessing overactive bladder syndrome and response to solifenacin treatment.用于评估膀胱过度活动症及索利那新治疗反应的中国膀胱过度活动症症状评分的翻译与验证
J Formos Med Assoc. 2014 Aug;113(8):506-12. doi: 10.1016/j.jfma.2012.07.044. Epub 2012 Oct 16.
9
Impact of fesoterodine on quality of life: pooled data from two randomized trials.非索罗定对生活质量的影响:两项随机试验的汇总数据
BJU Int. 2008 Jul;102(1):56-61. doi: 10.1111/j.1464-410X.2008.07710.x.
10
Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine.用托特罗定治疗的膀胱过度活动症患者症状改善与膀胱状况、症状困扰及健康相关生活质量的患者评估之间的关系。
Int J Clin Pract. 2008 Jun;62(6):925-31. doi: 10.1111/j.1742-1241.2008.01778.x.

引用本文的文献

1
Health utility value of overactive bladder in Japanese older adults.日本老年人群膀胱过度活动症的健康效用值
BJUI Compass. 2024 Nov 24;6(1):e471. doi: 10.1002/bco2.471. eCollection 2025 Jan.
2
The impact of pharmacotherapy on sexual function in female patients being treated for idiopathic overactive bladder: a systematic review.药物治疗对特发性膀胱过度活动症女性患者性功能的影响:系统评价。
BMC Womens Health. 2024 May 16;24(1):290. doi: 10.1186/s12905-024-03103-1.
3
Transcutaneous tibial neurostimulation and Solifenacin in urgent incontinence of postmenopausal women.
经皮胫神经刺激与索利那新治疗绝经后女性急迫性尿失禁
Eur J Transl Myol. 2023 Jun 20;33(2):11358. doi: 10.4081/ejtm.2023.11358.
4
Interpretation of the Meaningfulness of Symptom Reduction with Vibegron in Patients with Overactive Bladder: Analyses from EMPOWUR.Vibegron 治疗膀胱过度活动症患者症状缓解的意义解读:来自 EMPOWUR 的分析。
Adv Ther. 2022 Feb;39(2):959-970. doi: 10.1007/s12325-021-01972-8. Epub 2021 Dec 18.
5
Long-term Outcome of Adenosine A2A Receptor Antagonist on Lower Urinary Tract Symptoms in Male Parkinson Disease Patients.腺苷A2A受体拮抗剂对男性帕金森病患者下尿路症状的长期疗效
Clin Neuropharmacol. 2018 May/Jun;41(3):98-102. doi: 10.1097/WNF.0000000000000281.
6
Urinary incontinence in women.女性尿失禁。
Nat Rev Dis Primers. 2017 Jul 6;3:17042. doi: 10.1038/nrdp.2017.42.
7
Reproducibility study of Overactive Bladder Symptom Score questionnaire and its response to treatment (RESORT) in Korean population with overactive bladder symptoms.韩国 OAB 症状人群中 Overactive Bladder Symptom Score 问卷的可重复性研究及其对治疗的反应(RESORT)。
Qual Life Res. 2014 Feb;23(1):285-92. doi: 10.1007/s11136-013-0440-7. Epub 2013 May 29.